The programme aims to minimise inequalities across England through three focus areas:
1. FH detection and lipid management optimisation
FH has an estimated population prevalence of 1 in 250 in the UK. If left undetected and untreated, 50% of men aged 50 and over, and 30% of women aged 60 and over, may develop chronic heart disease by the age of 50 and could suffer a heart attack.
Sources: Family Heart, Public Health England
We’re working to expand access to genetic testing for FH via screening of electronic records and piloting a process of child-parent screening. This will enable early cascade testing and treatment for those at genetic risk of sudden cardiac death.
2. Access to appropriate medicines, including novel therapies such as PCSK9i and Inclisiran
We’re widening patient access to appropriate medicines for lipid treatment using the NICE endorsed summary of national guidance for lipid management for primary and secondary prevention of CVD.
3. Education to healthcare professionals
In order to provide clinicians and others with an interest in the programme with the opportunity to learn about different elements of the lipid management pathway, HEART UK has partnered with the NHS Accelerated Access Collaborative (AAC) and the Health Innovation Network to provide a comprehensive and varied education programme for healthcare professionals.